[Neonatal hemochromatosis].
Neonatal haemochromatosis is a disorder which affects foetuses and newborns. It is characterized by hepatocellular insufficiency, often appearing on the first day of life in the form of coagulopathy, hypoalbuminemia, hypoglycemia and jaundice. While spontaneous recovery has been reported, most of these infants die, and the diagnosis was previously often made during autopsy. With the help of MRI and salivary gland biopsies, plus increasing awareness of this disorder, the diagnosis is now often made quite early, and successful liver transplantations have been reported. Recently, there have also been encouraging preliminary reports of successful intervention with antioxidant and chelation pharmacotherapy, using a combination of selenium, vitamin E, N-acetylcysteine, deferoxamine, and prostaglandin E. We describe two patients with neonatal haemochromatosis who were both treated with this new "cocktail", one of whom died at five days of age, while the other survived, but needed a liver transplant at 2 1/2 months of age. The pathology of this condition is characterized by hepatic cirrhosis with giant cell transformation, and by siderosis of extrahepatic tissues. The prognosis is poor, and our experience with antioxidant treatment has been disappointing. Liver transplantation is a therapeutic option, but its use is limited by the scarcity of donor organs and the small size of many of the patients.
Sigurdsson
L
L
Pediatric Gastroenterology, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
Hansen
T W
TW
D000975:Antioxidants / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006432:Hemochromatosis / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007231:Infant, Newborn; D007502:Iron Chelating Agents / Q000627:therapeutic use; D016031:Liver Transplantation; D011379:Prognosis
D000975:Antioxidants; D007502:Iron Chelating Agents